Michael Kauffman is an accomplished leader in the biotechnology sector, holding prominent positions such as Chairman of the Board at FoRx Therapeutics, CEO and President of Nereid Therapeutics, and Chairperson of the Board at Incendia Therapeutics. Michael also co-founded Karyopharm Therapeutics Inc., where responsibilities included serving as Senior Clinical Advisor and CEO. Additionally, Michael has contributed as Lead Director and Board Member at Verastem Oncology. Michael earned an MD and PhD from The Johns Hopkins University School of Medicine, complemented by an educational background from Amherst College.